---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060026"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:25:35.084401+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Renalytix Q3 revenue $0.5M; net loss $7.7M; strategic sale process initiated

## Summary
- Revenue of $0.5M, down from $0.7M YoY; net loss narrowed to $7.7M from $12.1M.
- Cash and equivalents $4.7M; operating cash burn $4.9M, down ~40% from prior quarter.
- Total test volume 806 (82% billable); primary care orders up 33% QoQ.
- Strategic sale process initiated with multiple potential acquirers in discussions.
- FDA-authorized kidneyintelX.dkd launched April 2024; Medicare coverage draft issued.

## SEC filing metadata
- accession: 0000950170-24-060026
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024060026/0000950170-24-060026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024060026/rnlx-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060026
- JSON: https://secwatch.observer/filing/0000950170-24-060026.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060026.txt

## Key facts
- Earnings Releases
  Renalytix plc reported the fiscal third quarter ended March 31, 2024 results: revenue $0.5 million, net income Net loss was $7.7 million.
  - Period: the fiscal third quarter ended March 31, 2024
  - Revenue: $0.5 million
  - Net income: Net loss was $7.7 million
  - Result: reported results
  source text: During the three months ended March 31, 2024, the Company recognized $0.5 million of revenue, compared to $0.7 million for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024060026/0000950170-24-060026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.